Epigenetic & microRNA Regulation Analysis Service for Cancer Signaling Pathway
Creative Biolabs bridges the critical gap in mapping functional connections between chromatin modifications, non-coding RNAs, and cytoplasmic signaling. We provide the technical architecture and expert insight to physically validate target engagement, monitor global chromatin opening, and track nuclear-relocalized molecules. Whether you are characterizing histone deacetylase inhibitors, methyltransferase inhibitors, or high-affinity modified oligonucleotide candidates, our platforms deliver the precise quantitative metrics required to advance your therapeutic pipelines.
Understanding Regulatory Mechanisms
Grounded in advanced research, this platform integrates chromatin modeling, nuclear translocation pathways, polycistronic clusters, and the epitranscriptomic demethylation cascade. Targeting these overlapping regulatory networks, where molecules and RNA demethylases dynamically control chromatin architecture, is essential for uncovering novel therapeutic targets and biomarkers to bypass systemic drug resistance. Creative Biolabs provides the high-resolution technologies necessary to map these networks with single-nucleotide precision. By resolving how transient molecules and epitranscriptomic modifications interact, our specialized service delivers the precise quantitative parameters required to validate drug mechanisms of action and confidently advance pipeline development. We help you successfully unlock hidden layers of genetic control to support oncology drug discovery.
Our Service Capabilities
Creative Biolabs provides a highly specialized suite of high-definition multi-omics profiling tools engineered to resolve post-transcriptional networks, chromatin dynamics, and epigenetic feedback loops in oncogenic research.
Epigenetic Chromatin Profiling
We map global DNA methylation, histone acetylation, and open chromatin landscapes using advanced assays, providing high-resolution, single-nucleotide maps of critical regulatory promoter regions and genomic enhancer sites for studies.
Dual-Compartment Small RNA Sequencing
Our platform isolates and sequences small RNA populations from separated nuclear and cytoplasmic fractions, allowing you to track nuclear translocation and physical targeting of promoter regions by regulatory molecules.
Epitranscriptomic RNA Analysis
We execute advanced immunoprecipitation sequencing to identify and quantify RNA methylation marks, determining how these modifications regulate downstream target transcript stability, cellular translation, and drug pathway rescue responses effectively.
Oligonucleotide Target Engagement
Our custom assays validate target binding for candidate synthetic oligonucleotide inhibitors, measuring physical hybridization, intracellular delivery efficiency, global transcriptomic profiles, and the functional restoration of downstream epigenetic signaling pathways.
Partnering with us means securing elite scientific expertise, rapid turnaround times, and robust deliverables designed to accelerate your strategic oncology drug discovery and development program.
Workflow
Our workflow is designed for maximum precision and speed, utilizing an integrated multi-omics pipeline. We have streamlined the process from initial sample receipt to final regulatory data mapping, ensuring consistent, high-fidelity results at every stage.
Publication
This review examines how epigenetic mechanisms, DNA methylation, histone modifications, and RNA methylation regulate microRNA expression in cancer. It highlights the bidirectional crosstalk between miRNAs and epigenetic machinery, where miRNAs (epi-miRNAs) target DNMTs, HDACs, and EZH2, forming regulatory loops often disrupted in tumors. The authors discuss the diagnostic and prognostic potential of miRNA methylation patterns and explore epigenetic drugs as therapeutic strategies to restore tumor-suppressive miRNAs, bridging bench research to clinical applications.
Fig.1 MicroRNA and epi-miRNA regulatory networks in cancer. 1
Why Choose Us?
Creative Biolabs stands at the forefront of tumor biology and research services, offering an integrated multi-omics platform that addresses the most complex regulatory networks in oncogenic research. While standard genomic profiling services analyze chromatin modifications, epitranscriptomics, and non-coding RNA networks in isolation, our proprietary pipeline maps their direct convergence simultaneously. This high-definition resolution allows researchers to observe how epigenetic writers and erasers cooperate with non-coding RNAs to control oncogenic signaling cascades. By providing physically validated interaction datasets instead of speculative computational predictions, we empower biopharmaceutical innovators to make critical pipeline decisions with confidence.
Experience the Creative Biolabs Advantage - Get a Quote Today.
FAQs
How does physical target validation compare to computational tools?
Computational tools produce speculative predictions often containing false positives. Our physical assays verify active complexes in live cell states, providing reliable, high-fidelity data for therapeutics.
Can you perform these analyses on extremely small samples?
Yes. Our proprietary protocols are optimized for limited input materials, including fine-needle aspirates and low-volume biological samples, ensuring consistent data quality even when using minimal materials.
How do you distinguish between cytoplasmic and nuclear-active molecules?
We utilize high-precision physical fractionation protocols to isolate nuclear and cytoplasmic compartments before extraction, enabling separate sequencing to identify molecules with distinct intracellular localization and activity.
Customer Review
-
Streamlined Target Identification
Using Creative Biolabs' epigenetic and microRNA regulation analysis service in our research has significantly improved our ability to map novel regulatory nodes in the MAPK pathway. - Dr. A***erson -
Reduced Validation Timelines
Using Creative Biolabs' epigenetic and microRNA regulation analysis service in our research has significantly improved the speed at which we validate oligonucleotide binding efficiency. - J***athan
Related Services
To help you achieve your oncology therapeutic and pathway discovery goals, Creative Biolabs offers several complementary, high-end services:
B Cell based Immunoprecipitation Assay Service
Creative Biolabs provides high-affinity B cell-based immunoprecipitation services to reduce non-specific binding, ensuring reliable protein interaction data, novel biomarker identification, and efficient drug target validation for your research needs.
Learn More →Single-cell Tools based Lineage Tracing Service
Creative Biolabs offers advanced multimodal single-cell sequencing and computational analysis, integrating epigenetic, transcriptomic, and spatial data to provide high-resolution lineage tracing and insights into tumor heterogeneity, clonal evolution, and therapy.
Learn More →How to Contact Creative Biolabs
Creative Biolabs is the premier global partner for deciphering the complex epigenetic and post-transcriptional networks driving oncology. Our cutting-edge, integrated platforms, covering DNA methylation, chromatin architecture, nuclear transport, and the epitranscriptomic demethylase axis, provide the high-definition datasets needed to accelerate your therapeutic pipelines.
Start your custom analysis today. Reach out to our specialist team for more information and to begin planning your unique project.
Reference
- Pajares, María J., et al. "Epigenetic regulation of microRNAs in cancer: shortening the distance from bench to bedside." International Journal of Molecular Sciences 22.14 (2021): 7350. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms22147350
Download our brochure